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Abstract Severe clinical myotonia can be physically dis-
abling and socially imparing but as yet there is no standard-
ized treatment regimen. The aim of our study is to present a
protocol to measure myotonia using quantitative muscle
assessment measures. The proposed protocol addresses two
main issues. Muscle strength is assessed in  8 muscles on the
right and on the left using a myometer (QMA, quantitative
muscle assessment) and by testing strength manually using
the 5-point MRC scale (5 = normal) in 15 muscles on the
right and on the left. Grip myotonia is assessed by: (a) mea-
suring 1/2 and 3/4 relaxation times (RT) after maximum vol-
untary contraction (MVC) using QMA apparatus; (b) func-
tional tests (time to open a fist 10 times, time to open and
squeeze the eyes 10 times, time to climb 10 steps starting
from a seated position, time to protrude the tongue 10 times,
time to step onto a chair 10 times; (c) subjective measures of
the severity of myotonia using an arbitrary 4-point scale (0 =
absent, 4 = severe); and (d) electromyography (EMG) relax-
ation times after MVC. Although QMA seems to be a reli-
able tool to measure myotonia, there are still a number of
unsolved issues. Further studies are needed to ensure the
ability of QMA to quantify myotonia and to guarantee the
reliability of the results for clinical research purposes. 
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Introduction
Myotonia is a phenomenon of delayed muscle relaxation
associated with repetitive electrical depolarization following
a single induced muscle contraction. Commonly, myotonia is
found in the myotonic dystrophies [1] and in the non-dys-
trophic myotonias like hyperkalemic periodic paralysis,
paramyotonia congenita and myotonia congenita (Table 1). 
Treatment of myotonia has been directed at electrical sta-
bilization of the muscle membrane mainly using antagonists
of voltage-dependent sodium channels, responsible for the
repetitive electrical activity which characterizes the myoton-
ic phenomenon. Myotonia has been previously assessed by
measuring the relaxation time necessary to completely open
the fist after maximum voluntary contraction (MCV) [2], by
self-evaluation arbitrary scales [3], by functional tests [3, 4],
and by myotonic afterdischarge after MCV on electromyog-
raphy (EMG) measurements [3]. However, the variability of
the myotonic phenomenon and the “warm-up” effect have
made quantification of myotonia difficult. Often, the percep-
tion is one of a semi-quantitative evaluation which may not
be sensitive enough to detect small changes or account for
the variability.
We propose a protocol (Table 2) to determine whether
quantitative muscle assessment can be considered a tool for
the investigation of myotonia and thus be a good indicator of
effective antimyotonic treatment for clinical and research
purposes.
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Protocol design
Patient selection
Subjects with the following disorders are studied: hyper-
kalemic periodic paralysis with myotonia (HyperKPP),
paramyotonia congenita (PC), myotonia congenita (MC), and
mildly affected myotonic dystrophies (DM1, DM2, DMn)
[1]. To avoid triggers, all subjects should be placed for 1 hour
in a room at controlled temperature (22° C), and  requested to
remain completely relaxed for 30 minutes. In the days prior
to the actual testing, the patients should avoid exercise and
should follow a strict diet with low-carbohydrate intake and
without foods very rich or very poor in potassium, according
to the disease involved. For women, tests should not be per-
formed during menses. Any myotonic treatment and any
other treatment which is not life-saving should be discontin-
ued at least one week before the test period.
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Exclusion criteria reflect the degree of muscle weakness.
If finger flexor strength scores are below 4 on MRC grading,
patients should be eliminated for assessment of myotonia.
Any patient scoring below 130 on MRC megascores should
not be included in the experimental design.
Assessment of muscle strength 
Strength is evaluated by manual muscle testing and by quan-
titative myometry. The accuracy and consistency of the data
should be ensured by having the same person (ideally a
trained physiotherapist) perform the test each time. 
Quantitative muscle assessment (QMA). The QMA protocol
measures: (i) the maximum force attained; (ii) rise time, i.e.
the time taken for the rising edge of the data to go from 10%
to 90% of the maximum; and (iii) sustain time, i.e. the time
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Table 1 Classification of myotonias
Inherited myotonia
Myotonic dystrophies
DM1 (myotonic dystrophy type 1, linked to chromosome 19q)
DM2/PROMM (myotonic dystrophy type 2/proximal myotonic myopathy on 3q-linked locus)
DMn (DM1-like phenotype unlinked to 3q-linked locus)
Drug-induced myotonia
Clofibrate
Chloroquine
Diazocholesterol
2,4 dichlorophenoxyacetate (2,3-D)
Pseudomyotonia
Acid maltase deficiency
Hypothyroidism
Table 2 Experimental protocol
Assessment of muscle strength
Quantitative muscle assessment (QMA), 11 muscles (maximum voluntary contraction, MVC)
Manual muscle strength testing (5-point MRC scale), 15 muscles (normal score, 150)
Assessment of myotonia
Subjective self-evaluation of severity  (0, absent; 1, mild; 2,  moderate; 3, severe)
Functional tests
Time to open a fist 10 times
Time to open and squeeze the eyes 10 times 
Time to climb 10 steps starting from a seated position
Time to protrude the tongue 10 times
Time to step onto a chair 10 times
Measure of relaxation times by QMA
50% of maximum voluntary contraction
75% of maximum voluntary contraction
Measure of relaxation time by EMG
MRC, Medical Research Council [5]
the force remains above 70% of the maximum. Strength was
tested  in the following muscles: hand finger flexors, shoul-
der abductors and adductors, ankle dorsiflexors, and thigh
and knee flexors and extensors.
Manual muscle strength (MRC). Strength is assessed in 10
muscles on the right and on the left in the upper limbs
(scapular fixators, biceps, triceps, wrist flexors and exten-
sors, short and long finger flexors, thumb opponent, and fin-
ger abductors and adductors) and in 5 muscles on the right
and on the left in the lower limbs (ileopsoas, quadriceps, tib-
ialis anterior, tibialis posterior and finger extensors). Muscle
strength is quantified using the 0-5 MRC scale by summing
the scores for each muscle group; a score of 5 indicates nor-
mal strength for all 15 muscles tested on the right and on the
left and corresponds to 150 MRC megascore in normal sub-
jects. Attention should be focused on finger flexors: finger
flexor strength is quantified using a hand-held grip
dynamometer. The patient is asked to exert the maximum
possible force for 3 seconds and the maximum voluntary
contraction (MVC) is calculated.
Assessment of myotonia
Assessment of myotonia includes: 
(i) Functional tests: time to open a fist 10 times, time to
open and squeeze the eyes 10 times, time to climb 10
steps starting from a seated position, time to protrude the
tongue 10 times, and time to step onto a chair 10 times; 
(ii) Subjective measures: self-evaluation of the severity of
myotonia using an arbitrary 4-point scale (0, absent; 1,
mild; 2, moderate; 3, severe); 
(iii) Objective measures: assessment of myotonia from relax-
ation times (RTs) at the end of the 3-second MVC pro-
duced by hand grip. Relaxation times are the time for the
MVC to decrease by 50% and 75% (referred to as 1/2
RT and 3/4 RT). Relaxation time values are accepted
only if subjects exert the same degree of strength as
measured in previous records of strength assessment
with QMA. To avoid the influence of the warm-up phe-
nomenon, we evaluate only the first grip and subsequent
relaxation. When necessary, we repeat the test on the
same subject, but not before 15 minutes have elapsed; 
(iv) EMG relaxation time determined from the myotonic
afterdischarge in the musculus opponens pollicis after
MVC.
Conclusions
Pharmacological treatment of myotonia is a subject of con-
troversy since a long list of various therapeutic agents have
been tried in myotonic disorders [6-11]. The rational for
treatment is dictated by the fact that many patients are dis-
abled by their difficulty in relaxation after a maximum vol-
untary contraction to the extent their quality of life is
impaired. On the other hand, the benefits of myotonia con-
trol must be weighed against the risk of antimyotonic
agents. In other diseases, improvement of myotonia may
unmask or worsen  muscle weakness. In addition, there is
no evidence that the prevention of myotonia, in those
myotonic syndromes associated with myopathy or  dystro-
phy, influences these features. However, in the majority of
patients antimyotonic treatment is justified. Despite these
considerations, there is still no standardised treatment reg-
imen for myotonia and there have been relatively few ran-
domized controlled trials for the quantification of myoto-
nia.
Although preliminary, we present an experimental pro-
tocol for the quantification of myotonia. Any patient with a
myotonic disorder can be studied as long as the inclusion
criteria for the degree of muscle strength are considered as
well  as the other criteria mentioned. This allows for a large
sampling size. We have included measures of muscle
strength although the protocol focuses on measures of
myotonia because we have often observed an inverse cor-
relation between muscle strength and degree of myotonia.
Moreover, several patients, especially those with myotonia
congenita or with proximal myotonic myopathy, have
reported increased weakness following antimyotonic thera-
py although the precise relationship between myotonic
stiffness and weakness is unclear. Assessment of myotonia
using this protocol design has emphasised a number of
problems related to this phenomenon. There is an extreme
variability of myotonia between patients with the same dis-
ease, but also within the same patient, from day to day and
even within the same day.  Factors affecting myotonia such
as outside temperature, menses and exercise should be
strictly controlled.  Keeping the patients in a resting condi-
tion before testing and considering only the first grip to
avoid the warm-up phenomenon may need further confir-
mation. The patient may not understand the test immedi-
ately and therefore give a partial result due to improper test
position or system malfunctioning. We believe the patient
should perform correctly because testing muscle strength
uses the same apparatus so that the patient should be famil-
iar with the hand-grip. Nonetheless, we have considered the
possibility of error and believe that the 15-minute interval
between one test and another one is sufficiently long to
avoid warm-up. This implicates that testing may be repeat-
ed at specific intervals of time, although this makes testing
lengthy and intolerable for the patient.
Although QMA seems to be a reliable tool to measure
myotonia, there are still a number of unsolved issues.
Further studies are needed to ensure the ability of QMA to
quantify myotonia and to guarantee the reliability of the
results for clinical research purposes.
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